Lipocine Inc (LPCN)
5.07
+0.39
(+8.33%)
USD |
NASDAQ |
May 06, 16:00
5.01
-0.06
(-1.18%)
After-Hours: 20:00
Lipocine Cash from Financing (Quarterly): -0.0053M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.0053M |
| September 30, 2023 | 0.4211M |
| June 30, 2023 | -0.0052M |
| March 31, 2023 | -0.006M |
| December 31, 2022 | -0.0059M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | -1.494M |
| March 31, 2022 | -0.6273M |
| December 31, 2021 | -0.8385M |
| September 30, 2021 | -0.8383M |
| June 30, 2021 | -0.8386M |
| March 31, 2021 | 29.44M |
| December 31, 2020 | 4.555M |
| September 30, 2020 | 4.662M |
| June 30, 2020 | 6.801M |
| March 31, 2020 | 4.880M |
| December 31, 2019 | 5.815M |
| September 30, 2019 | -0.1735M |
| June 30, 2019 | -0.5521M |
| March 31, 2019 | 5.230M |
| December 31, 2018 | 0.5616M |
| September 30, 2018 | 0.0908M |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 10.00M |
| Date | Value |
|---|---|
| December 31, 2017 | 0.0462M |
| September 30, 2017 | 2.384M |
| June 30, 2017 | 5.709M |
| March 31, 2017 | 3.087M |
| December 31, 2016 | 0.5716M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.0342M |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.0576M |
| June 30, 2015 | 32.52M |
| March 31, 2015 | 0.1369M |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.0161M |
| March 31, 2014 | -0.2712M |
| December 31, 2013 | 12.54M |
| September 30, 2013 | 35.94M |
| June 30, 2013 | 0.00 |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 0.0405M |
| September 30, 2012 | -0.0405M |
| June 30, 2012 | 0.0405M |
| March 31, 2012 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.494M
Minimum
Jun 2022
29.44M
Maximum
Mar 2021
2.694M
Average
-0.0053M
Median
Dec 2023
Cash from Financing (Quarterly) Benchmarks
| Alpine Immune Sciences Inc | 156.61M |
| Eliem Therapeutics Inc | 0.288M |
| NovaBay Pharmaceuticals Inc | -0.026M |
| Palatin Technologies Inc | 4.974M |
| iBio Inc | 4.005M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.022M |
| Cash from Investing (Quarterly) | 2.727M |
| Free Cash Flow | -11.88M |
| Free Cash Flow Per Share (Quarterly) | -0.3821 |
| Free Cash Flow to Equity (Quarterly) | -2.032M |
| Free Cash Flow to Firm (Quarterly) | -2.032M |
| Free Cash Flow Yield | -44.97% |